ALNYLAM PHARMACEUTICALS, INC. (ALNY) revenue & profit
ALNYLAM PHARMACEUTICALS, INC. (ALNY): revenue $3.7B, net income $313.7M in 2025; latest quarter +66.9% year over year. From SEC filings.
$3.7BRevenue 2025
TickerALNY (Nasdaq)
IndustryHealthcare · Pharmaceutical Preparations
Revenue 2025$3.7B
Net income 2025$313.7M
Net margin8.4%
Annual revenue growth+65.2%
Latest quarter (2026 Q2) · Revenue$1.3B
vs. same quarter last year+66.9%
Latest quarter · Net income$164.5M
Annual revenue & net income
| Year | Revenue | Net income | |
|---|---|---|---|
| 2022 | $1B | -$1.1B | |
| 2023 | $1.8B | -$440.2M | |
| 2024 | $2.2B | -$278.2M | |
| 2025 | $3.7B | $313.7M |
ℹ️ Not investment advice. Calendar-year figures as tagged by the SEC; a company’s fiscal year may end in a different month.